Back to discover
Drug

Ad26COVS1

In clinical development
Emerging researchLate-stage development
Also known as COVID-19 (SARS-CoV-2) vaccine, Ad26, COVID-19 VACCINE ADENOVIRUS-26, COVID-19 vaccine, Ad26.COV2.S (Janssen), SARS-COV-2 (COVID-19) vaccine, vector - Ad26+3 more

COVID-19 (SARS-CoV-2) vaccine, Ad26, COVID-19 VACCINE ADENOVIRUS-26, COVID-19 vaccine, Ad26.COV2.S (Janssen), SARS-COV-2 (COVID-19) vaccine, vector - Ad26, Ad26.COV2.S, SARS-CoV-2 (COVID-19) Ad26 vaccine, recombinant, SARS-CoV-2 Ad26 vaccine, recombinant.

RxNorm2479830UNIIJT2NS6183B
2
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older

Clinical trial2025-05-25Results posted · ClinicalTrials.gov

An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants

Clinical trial2025-05-25Results posted · ClinicalTrials.gov

A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Clinical trial2025-04-20Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of Ad26.COV2.S Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive

Clinical trial2025-02-04Results posted · ClinicalTrials.gov

Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)

Clinical trial2024-03-28Terminated · ClinicalTrials.gov

Tracking the COVID-19 vaccines: The global landscape.

Research2023-03-30Human vaccines & immunotherapeutics

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

Research2023-03-07Viruses

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ad26COVS1
Aliases & brands
COVID-19 (SARS-CoV-2) vaccine, Ad26COVID-19 VACCINE ADENOVIRUS-26COVID-19 vaccine, Ad26.COV2.S (Janssen)SARS-COV-2 (COVID-19) vaccine, vector - Ad26Ad26.COV2.SSARS-CoV-2 (COVID-19) Ad26 vaccine, recombinantSARS-CoV-2 Ad26 vaccine, recombinant
RxNorm CUI
2479830
UNII
JT2NS6183B

Clinical trials

15 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
15
registered trials across all phases
LATEST COMPLETION 2023
4
Late-stage (III+)
12
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 15
Phase 12Phase 1 / 22Phase 27Phase 34

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults

CompletedPH IIIKey trialJanssen Vaccines & Prevention B.V.n=1,6092023

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

CompletedPH IIIKey trialJanssen Vaccines & Prevention B.V.n=31,8352023

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

CompletedPH IIIKey trialJanssen Vaccines & Prevention B.V.n=44,3252023

A Randomized, Double-blind, Phase 3 Study to Evaluate Safety, Reactogenicity, and Immunogenicity of Co-administration of Ad26.COV2.S and Influenza Vaccines in Healthy Adults 18 Years of Age and Older

CompletedPH IIIJanssen Vaccines & Prevention B.V.n=8612022

Recent completions

Trials that read out recently, adding to the completed evidence base.

An Open-label, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants

CompletedPH IIJanssen Vaccines & Prevention B.V.n=512023

A Randomized, Observer-blind, Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive

CompletedPH IIJanssen Vaccines & Prevention B.V.n=3042023

A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COV2.S Administered As a Two-Dose Schedule in Healthy Adults

CompletedPH IIIKey trialJanssen Vaccines & Prevention B.V.n=1,6092023

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

CompletedPH IIIKey trialJanssen Vaccines & Prevention B.V.n=31,8352023

A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

CompletedPH I/IINational Institute of Allergy and Infectious Diseases (NIAID)n=8672023

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older

CompletedPH IIIKey trialJanssen Vaccines & Prevention B.V.n=44,3252023

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

Viruses · 2023 · 125 cites

Tracking the COVID-19 vaccines: The global landscape.

Human vaccines & immunotherapeutics · 2023 · 43 cites
Recent papers

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?

Viruses · 2023 · 125 cites

Tracking the COVID-19 vaccines: The global landscape.

Human vaccines & immunotherapeutics · 2023 · 43 cites
Major research themes4
COVID-191COVID-19 Vaccines1Genetic Therapy1Genetic Vectors1
Journals, researchers & institutions
Top journals
  • Human vaccines & immunotherapeutics1
  • Viruses1
Leading researchers
  • Kumar S1
  • Lundstrom K1
  • Mishra G1
  • Saxena SK1
  • Yadav T1
Leading institutions
free-text, unnormalised
  • Centre for Advanced Research (CFAR)1
  • Jawaharlal Nehru Smriti Government Post Graduate College1
  • Meerut Institute of Engineering and Technology1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

ChAdOx1 nCoV-19

Studied across 3 of the same disease areas as Ad26COVS1 in the shared literature.

3 shared diseases2 shared papers
COVID-19 Vaccines

Studied across the same disease area as Ad26COVS1 in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials